Key facts
- This page summarizes John Nosenzo's Form 4 filing for Bioventus Inc. (BVS).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Apr 2023, 17:45.
John Nosenzo - 01 Apr 2022 Form 4 Insider Report for Bioventus Inc. (BVS)
- Reporting relationship
- Fmr. Chief Commercial Officer
- Issuer ticker
- BVS
- Reported as of
- 01 Apr 2022
- Net transaction value
- -$1,251
- SEC form
- 4
- Accepted by SEC
- 21 Apr 2023, 17:45:03 UTC
- Prior SEC filing
- 15 Feb 2022
- Next SEC filing
- 02 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/Anthony D'Adamio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Nosenzo filed Form 4 for Bioventus Inc. (BVS) on 21 Apr 2023.
Change
- Previous filing in this sequence was filed on 15 Feb 2022.
- Current net transaction value: -$1,251.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BVS
transaction
Class A Common Stock
Sale
- Transaction value
- $563
- Shares
- -40
- Change %
- -0.05%
- Price
- $14.07
- Shares after
- 87,250
- Date
- 01 Apr 2022
- Ownership
- Direct
- Footnotes
- F1, F2
BVS
transaction
Class A Common Stock
Sale
- Transaction value
- $639
- Shares
- -95
- Change %
- -0.11%
- Price
- $6.73
- Shares after
- 87,155
- Date
- 01 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
BVS
transaction
Class A Common Stock
Sale
- Transaction value
- $49
- Shares
- -7
- Change %
- -0.01%
- Price
- $7.00*
- Shares after
- 87,148
- Date
- 03 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
Reflects shares sold to cover taxes in connection with shares purchased under the Company's 2021 Employee Stock Purchase Plan.
Footnote F2
Includes an aggregate of 3,398 shares of Class A common stock purchased under the Company's 2021 Employee Stock Purchase Plan. This number has also been adjusted to account for a scrivener's error in a prior filing which attributed an acquisition of 40 shares under the Company's 2021 Employee Stock Purchase Plan.